Literature DB >> 2412119

Reduction of biogenic amine levels in the Rett syndrome.

H Y Zoghbi, A K Percy, D G Glaze, I J Butler, V M Riccardi.   

Abstract

The Rett syndrome is a progressive disorder in female patients that is characterized by autistic behavior, dementia, ataxia, loss of purposeful use of the hands, and seizures. The results of laboratory investigations are usually normal, with the exception of electroencephalography. In an attempt to understand the pathogenesis of this syndrome, we assayed biogenic amine metabolites in the cerebrospinal fluid of six patients, 2 to 15 years of age. 3-Methoxy-4-hydroxyphenylethylene glycol (MHPG, a metabolite of norepinephrine), homovanillic acid (a metabolite of dopamine), and 5-hydroxyindoleacetic acid (5-HIAA, a metabolite of serotonin) were quantitated by a method involving gas chromatography and mass spectrometry. Levels of MHPG and homovanillic acid were significantly reduced in all the patients as compared with those in controls of similar age (P = 0.01 and 0.008, respectively). The reduction in the level of 5-HIAA was not significantly different from that in the controls (P = 0.15). These findings suggest an underlying disorder of biogenic amines in the Rett syndrome and may provide new insight into its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412119     DOI: 10.1056/NEJM198510103131504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  34 in total

1.  Profile of Huda Y. Zoghbi.

Authors:  Regina Nuzzo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 2.  Breathing dysfunction in Rett syndrome: understanding epigenetic regulation of the respiratory network.

Authors:  Michael Ogier; David M Katz
Journal:  Respir Physiol Neurobiol       Date:  2008-12-10       Impact factor: 1.931

3.  The American history of Rett syndrome.

Authors:  Alan Percy
Journal:  Pediatr Neurol       Date:  2013-11-05       Impact factor: 3.372

Review 4.  Rett syndrome: a review of current knowledge.

Authors:  R Van Acker
Journal:  J Autism Dev Disord       Date:  1991-12

5.  β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.

Authors:  Nikolaos Mellios; Jonathan Woodson; Rodrigo I Garcia; Benjamin Crawford; Jitendra Sharma; Steven D Sheridan; Stephen J Haggarty; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

6.  Neuropathology of Rett syndrome.

Authors:  K Jellinger; D Armstrong; H Y Zoghbi; A K Percy
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 7.  The serotonergic anatomy of the developing human medulla oblongata: implications for pediatric disorders of homeostasis.

Authors:  Hannah C Kinney; Kevin G Broadbelt; Robin L Haynes; Ingvar J Rognum; David S Paterson
Journal:  J Chem Neuroanat       Date:  2011-05-27       Impact factor: 3.052

8.  Methyl CpG Binding Protein 2 Gene Disruption Augments Tonic Currents of γ-Aminobutyric Acid Receptors in Locus Coeruleus Neurons: IMPACT ON NEURONAL EXCITABILITY AND BREATHING.

Authors:  Weiwei Zhong; Ningren Cui; Xin Jin; Max F Oginsky; Yang Wu; Shuang Zhang; Brian Bondy; Christopher M Johnson; Chun Jiang
Journal:  J Biol Chem       Date:  2015-05-15       Impact factor: 5.157

9.  Electron-dense lipidic capillary deposits in Rett syndrome.

Authors:  R Dieler; J M Schröder; K Reddemann
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

10.  Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities.

Authors:  Rodney C Samaco; Caleigh Mandel-Brehm; Hsiao-Tuan Chao; Christopher S Ward; Sharyl L Fyffe-Maricich; Jun Ren; Keith Hyland; Christina Thaller; Stephen M Maricich; Peter Humphreys; John J Greer; Alan Percy; Daniel G Glaze; Huda Y Zoghbi; Jeffrey L Neul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.